Company Filing History:
Years Active: 1995-1998
Title: Takanori Ichikawa: Innovator in Monoclonal Antibody Development
Introduction
Takanori Ichikawa is a prominent inventor based in Takasaki, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 2 patents, his work has advanced the detection of human G-CSF, a crucial component in medical diagnostics.
Latest Patents
Ichikawa's latest patents include a method for selecting monoclonal antibodies for human G-CSF permitting. This invention relates to a high affinity monoclonal antibody for human G-CSF and an enzyme immunoassay utilizing this antibody. The method allows for the low-level detection of G-CSF in plasma, achieving sensitivity equal to or less than 0.5 pg/ml without interference from human fluids. Another notable patent is for monoclonal antibodies and a method for determining human G-CSF. This invention enables the measurement of trace amounts of human G-CSF in body fluids from patients with hematological disorders, ensuring accurate detection at concentrations as low as 0.5 pg/ml.
Career Highlights
Ichikawa is currently associated with Kirin-Amgen, Inc., where he continues to innovate in the field of biotechnology. His work has been instrumental in enhancing diagnostic techniques, particularly in hematology.
Collaborations
He has collaborated with notable colleagues such as Tomoaki Kuwaki and Shigeru Matsuki, contributing to the advancement of their shared research goals.
Conclusion
Takanori Ichikawa's contributions to the field of monoclonal antibodies have paved the way for improved diagnostic methods in medicine. His innovative patents reflect his commitment to advancing healthcare through biotechnology.